Skip navigation
Pipeline CandidatesOre Pharmaceuticals currently has one compound, GL1001, in active preclinical development. Evaluation by the Indication-Seeking Program has led to the discovery of potential benefit of this compound in gastrointestinal inflammation and other related diseases and conditions. An IND is in preparation so that a planned 2008 clinical trial may enroll subjects in the United States.  |